Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
This trial is active, not recruiting.
|Treatments||doxorubicin, cyclophosphamide, paclitaxel, surgery|
|Sponsor||Barretos Cancer Hospital|
|Collaborator||University of Sao Paulo|
|Start date||July 2008|
|End date||April 2012|
|Trial size||80 participants|
|Trial identifier||NCT00820690, 135/2008|
The purpose of this study is to analyze gene expression signature and immunohistochemical markers associated with clinical and pathological response to neoadjuvant chemotherapy in locally advanced breast cancer.
Clinical objective and pathological responses to chemotherapy
time frame: 8 months
Clinical, radiologic and pathologic correlation
time frame: 3 years
time frame: 5 years
Overall actuarial survival
time frame: 5 years
Pathologic complete response
time frame: 9 months
Female participants from 18 years up to 70 years old.
Inclusion Criteria: - Women with locally advanced women breast cancer - Histology: ductal ou lobular invasive histology - Agreement to take part in the study and signature of the informed consent - Clinical condition to receive doxorubicin/cyclophosphamide and paclitaxel - ECOG 0 or I Exclusion Criteria: - Not clinical stage III - Inflammatory breast cancer - Previous treatment - Previous diagnosis of cancer (except basal cell or squamous cell skin carcinoma and non-invasive cervical carcinoma) - Pregnancy - Absence of clinical condition to receive chemotherapy
|Official title||Gene Expression Signature and Immunohistochemical Markers Associated With Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer|
|Description||Locally advanced breast cancer is a common condition in development countries. Neoadjuvant chemotherapy gives the opportunity to identify genetic signatures associated with objective clinical and pathological complete responses. Patients will receive doxorubicin/cyclophosphamide with paclitaxel. Tumor samples collected before and after chemotherapy will be analyzed.|
Call for more information